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Recent studies have demonstrated the importance of endoplasmic reticulum aminopeptidase (ERAP) in blood pressure (BP)
homeostasis. To date, no large prospective, genetic–epidemiological data are available on genetic variation within ERAP and
hypertension risk. The association of 45 genetic variants of ERAP1 and ERAP2 was investigated in 17,255 Caucasian female
participants from the Women’s Genome Health Study. All subjects were free of hypertension at baseline. During an 18-year
follow-up period, 10,216 incident hypertensive cases were identiﬁed. Multivariable linear, logistic, and Cox regression analyses
were performed to assess the relationship of genotypes with baseline BP levels, BP progression at 48 months, and incident
hypertension assuming an additive genetic model. Linear regression analyses showed associations of four tSNPs (ERAP1:
rs27524; ERAP2: rs3733904, rs4869315, and rs2549782; all p < 0 05) with baseline systolic BP levels. Three tSNPs (ERAP1:
rs27851, rs27429, and rs34736, all p < 0 05) were associated with baseline diastolic BP levels. Multivariable logistic regression
analysis showed that ERAP1 rs27772 was associated with BP progression at 48 months (p = 0 0366). Multivariable Cox
regression analysis showed an association of three tSNPs (ERAP1: rs469783 and rs10050860; ERAP2: rs2927615; all p < 0 05)
with risk of incident hypertension. Analyses of dbGaP for genotype–phenotype association and GTEx Portal for gene expression
quantitative trait loci revealed ﬁve tSNPs with diﬀerential association of BP and nine tSNPs with lower ERAP1 and ERAP2
mRNA expression levels, respectively. The present study suggests that ERAP1 and ERAP2 gene variation may be useful for risk
assessment of BP progression and the development of hypertension.
1. Introduction
Elevated blood pressure is an important risk factor for the
development of stroke, heart failure, and cardiovascular and
renal disease. However, elevated blood pressure is controlled
in only 54% of the US population with hypertension [1]. This
is due, in part, to the fact that the pathophysiology of elevated
blood pressure/hypertension is not entirely clear.
Endoplasmic reticulum aminopeptidase-1 (ERAP1; gene
ID 51752, Chr. 5q15) and -2 (ERAP2; gene ID 64167, Chr.
5q15) are multifunctional aminopeptidases that have been
proposed to play important roles in the pathophysiology of
inﬂammatory and immune disorders associated with the
major histocompatibility complex class I (MHC-I), pre-
eclampsia, and hypertension [2–4]. ERAP1 and ERAP2 are
zinc metallopeptidases that are members of the M1
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oxytocinase subfamily that work in concert to catalyze the
cleavage of amino acids from the N-terminus of various
human antigens and peptide hormones [4–6] and have been
shown to be widely expressed in human tissue including the
heart, endothelial cells, and kidney. They are proposed to reg-
ulate blood pressure by inactivation of angiotensin II (AngII).
In vitro, ERAP1 catalyzes the conversion of AngII to
angiotensin III and IV [5], and ERAP2 converts angiotensin
III to angiotensin IV [6]. Recent studies have shown that
ERAP1 binds to thioredoxin ERp44 within the endoplasmic
reticulum and that global ablation of ERp44 in mice leads
to increased circulating levels of ERAP1 and reduced blood
pressure and AngII levels in vivo—results that are consistent
with a role of ERAP1 in blood pressure homeostasis [7]. Fur-
thermore, genetic–molecular approaches have identiﬁed var-
iants among ERAP1 and ERAP2 genes that are associated
with preeclampsia [8, 9], hemolytic uremia [10], and hyper-
tension [11]. In particular, an association between the ERAP1
rs30187 gene variant and hypertension was reported in a
small cohort of 143 hypertensive and 348 normotensive Jap-
anese subjects. Of importance, this variant was associated
with reduced trimming eﬃciency of ERAP1 to inactivate
AngII and increase bradykinin levels [12]. Moreover, there
is evidence showing that hypertensive carriers of this genetic
variant with left ventricular hypertrophy have signiﬁcantly
better left ventricular mass index responses to the AngII type
1 receptor antagonist than noncarriers have—results that
implicate AngII and ERAP1 as potential regulators of left
ventricular mass [13]. However, case–control genetic associ-
ation analyses of the MRC British Genetics of Hypertension
study participants showed no association between genetic
variants at the ERAP1 locus and essential hypertension in
1700 hypertensive and 1700 normotensive subjects [14, 15].
Furthermore, genetic variants of ERAP loci have not been
reported to be associated with blood pressure in genome-
wide association studies [16–20].
However, to date, no systematic, prospective epidemio-
logical data are available that examine the relevance of the
ERAP1 and ERAP2 gene loci as risk markers for hyperten-
sion. We thus evaluated the potential association of 33
ERAP1 and 12 ERAP2 tagging single-nucleotide polymor-
phisms (tSNPs) with (i) baseline systolic and diastolic blood
pressure, (ii) blood pressure progression, and (iii) incident
hypertension in a large prospective cohort of 17,255 initially
healthy US white women.
2. Materials and Methods
2.1. Study Design. Details of the study design have been pre-
viously described [21, 22]. In brief, participants in the
Women’s Genome Health Study (WGHS)—a genetic sub-
study of the Women’s Health Study [23, 24]—included ini-
tially healthy North American women aged 45 or older
with no previous history of cardiovascular disease, cancer,
or other major chronic illnesses. A baseline blood sample
was collected during the enrollment phase of the Women’s
Health Study between 1992 and 1995. Study participants,
who gave an informed consent for blood-based analyses
related to risks of incident chronic diseases, were followed
up for incident events that were adjudicated by an endpoints
committee using standardized criteria and a full medical
record review [23, 24]. The present investigation included
17,255 Caucasian participants of the WGHS; all were free
of known cardiovascular disease, cancer, and hypertension
at baseline. During a median follow-up time of 11.46 years
(interquartile range: 6.52 to 18.68 years) for this sample pop-
ulation, a total of 10,216 newly diagnosed hypertensive cases
were identiﬁed. The Brigham andWomen’s Hospital Institu-
tional Review Board for Human Subjects Research approved
the study protocol.
2.2. Study Variables. Blood pressure at randomization was
self-reported by the participants, a group where self-report
of blood pressure has proven highly accurate [25–27].
Women were classiﬁed into 3 predeﬁned blood pressure cat-
egories: <120mmHg for systolic and 75mmHg for diastolic
blood pressure; 120 to 129mmHg for systolic or 75 to
84mmHg for diastolic blood pressure; and 130 to 139mmHg
for systolic or 85 to 89mmHg for diastolic blood pressure
[28]. Women with discordant systolic and diastolic blood
pressure categories were classiﬁed into the higher category.
Covariables of interest were ascertained at study entry and
included age, smoking status, history of hyperlipidemia
(≥240mg/dL or 6.22mmol/L), body mass index (BMI;
weight in kilograms divided by the square of height in
meters), history of diabetes, frequency of exercise, alcohol
consumption, and highest education level achieved.
2.3. Outcome Assessment. To assess blood pressure progres-
sion, we created categories of self-reported blood pressure
at 48 months of follow-up identical to those at baseline as
previously described [21, 22]. Blood pressure progression
was deﬁned by progressing ≥1 blood pressure category com-
pared with baseline or by a new diagnosis of hypertension
during the ﬁrst 48 months. Incident cases of hypertension
were deﬁned by meeting ≥1 of the following criteria: self-
report of a new physician diagnosis of hypertension assessed
at years 1 and 3 and yearly thereafter; self-report of antihyper-
tensive treatment assessed at years 1, 3, and 4; or self-reported
systolic blood pressure of ≥140mmHg or diastolic blood
pressure of ≥90mmHg assessed at years 1 and 4. Women
reporting a new physician diagnosis of hypertension also pro-
vided month and year of diagnosis. For a diagnosis deﬁned by
another criterion or amissing date for a physician diagnosis, a
date between the current and the previous questionnaire was
randomly assigned. Women who developed cardiovascular
disease, for which the management may aﬀect blood pressure
levels, were censored at the date of diagnosis and not consid-
ered at risk for incident hypertension thereafter.
2.4. Genotype Determination. As described elsewhere, DNA
extracted from the baselineWGHS blood samples underwent
tSNP (r2 ≈ 0 80) genotyping using the genome-wide Illumina
Inﬁnium II HumanHap300 panel [29, 30]. Genotyping call
rates were >99% per SNP.
2.5. GTEx mRNA Expression Proﬁle in Cardiovascular
Tissues. To determine the relationship between gene variants
and mRNA expression levels, we explored publicly available
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Expression Quantitative Trait Loci (eQTL) data [31] for
ERAP1 and ERAP2 in human coronary and tibial arteries,
adrenal gland, and left ventricle tissues. The eQTL data
presented were obtained from the Genotype-Tissue Expres-
sion (GTEx) Project consortium: GTEx Analysis Release
V6p (dbGaP Accession phs000424.v6.p1). Eﬀect estimates
and p values were directly extracted from the GTEx dataset
summary statistics report (https://gtexportal.org/home/).
2.6. Quantitative Real-Time PCR (qPCR) in Human
Endothelial Cells.No (in vitro) data are available on the inter-
play between various blood pressure regulatory peptides and
ERAPs in relation to expression levels. In vitro, AngII acti-
vates endothelial cells, leading to increased angiogenesis
and reactive oxygen species production among other eﬀects
[32–34]. For the present in vitro studies, the human endothe-
lial cell line, EA.hy926 (American Type Culture Collection:
CRL-2922), was used; this cell line was previously docu-
mented by us and others to be responsive to AngII and
aldosterone activation [32–34]. The eﬀects of AngII on
ERAP1 as well as ERAP2 gene expression were investigated.
In brief, cells were grown in 10% fetal bovine serum-
Dulbecco’s Modiﬁed Eagle Medium and split 1 : 16 at
conﬂuence [33, 34]. Cells were then treated for 24 hours with
AngII (10 nM) in the presence or absence of losartan (1μM),
an AngII type I receptor antagonist. Total RNA was extracted
using the RNeasy Mini kit (Qiagen Sciences, Hilden,
Germany) following the manufacturer’s instructions.
cDNA was synthesized from 3μg of total RNA with the
First Strand cDNA Synthesis kit (Amersham, Little Chalfont,
United Kingdom). PCR ampliﬁcation reactions were per-
formed with TaqMan gene expression assays for ERAP1
(Hs00429970_m1) and ERAP2 (Hs01073631_m1) in tripli-
cate with the ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA). The cycle threshold
method was used following the manufacturer’s recommen-
dation to determine mRNA levels. Target gene expression
was normalized to glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) and 18S rRNA levels.
2.7. Statistical Analyses. Genotype frequencies were
compared with values predicted by the Hardy–Weinberg
equilibrium using the chi-square test with one degree of free-
dom. Multivariable linear regression analysis, adjusting for
age, BMI, history of diabetes, history of hyperlipidemia,
current smoking status, exercise, alcohol use, education level,
and current (any) hormone use, was performed to assess the
relationship of genotypes with baseline blood pressure mea-
surements. Multivariable logistic regression analysis was
performed to examine the associations between genotypes
and blood pressure progression at 48 months, adjusting for
age, BMI, history of diabetes, history of hyperlipidemia, cur-
rent smoking status, exercise, alcohol use, education level,
current (any) hormone use, and randomized treatment
assignments. Hazard ratios (HRs) associated with each of
the SNPs were calculated separately by Cox regression analy-
sis, adjusting for age, BMI, history of diabetes, history of
hyperlipidemia, current smoking status, exercise, alcohol
use, education level, current (any) hormone use, and
randomized treatment assignments. The proportional haz-
ards assumption was examined for all of the models by
including a genotype by logarithm of time interaction into
each model. All analyses were carried out using SAS v9.1
package (SAS Institute Inc.) or R software, assuming an
additive model for genetic eﬀects. Because of the conﬁrma-
tory nature of the current study and the extended data
from several public consortia, a 2-tailed uncorrected (for
multiple testing) p value of 0.05 was considered a statisti-
cally signiﬁcant result.
3. Results
3.1. ERAP1 and ERAP2 Variants with Baseline Blood
Pressure, Blood Pressure Progression, and Risk of
Hypertension. The baseline characteristics of the 17,255 ini-
tially healthy Caucasian women are shown in Table 1. Two
(rs17482078 and rs25866) out of the 45 SNPs evaluated were
not in the Hardy–Weinberg equilibrium with uncorrected
Table 1: Baseline characteristics of the study population.
Variable N = 17,255
Age, years 52.00 [48.00, 57.00]
Body-mass index, kg/m2 24.21 [22.05, 27.40]
Smoking status, %
Current 11.88
Past 37.24
Never 50.88
History of diabetes, % 1.29
History of hyperlipidemia ≥240mg/dL, % 24.98
Exercise, times/week, %
Rarely/never 35.19
<1 19.80
1 to 3 33.11
>3 11.89
Alcohol use, %
Rarely/never 41.41
Monthly 13.45
Weekly 34.42
Daily 10.71
Highest education level, %
Less than a Bachelor’s degree 53.67
Bachelor’s degree 24.97
Master’s or doctoral degree 21.37
Aspirin use, % 49.71
Beta-carotene use, % 49.92
Vitamin-E use, % 50.38
Current hormone use, % 43.32
Baseline BP category, %
<120/75mmHg 44.76
120–129/75–84mmHg 39.14
130–139/85–89mmHg 16.10
Data are median and interquartile range for continuous, and percentages for
categorical variables.
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Table 2: Logistic regression analysis for all SNPs evaluated with
blood pressure progression.
dbSNP MA MAF OR Lower95% CI
Upper
95% CI p-uncorrected
ERAP1
rs1559085 G 0.1413 1.056 0.988 1.129 0.1094
rs27851 G 0.0607 0.946 0.858 1.043 0.2686
rs3756623 C 0.0750 0.970 0.888 1.059 0.4924
rs754615 C 0.3907 1.014 0.967 1.064 0.5581
rs1862609 A 0.3129 1.022 0.973 1.075 0.3846
rs27772 G 0.3133 0.948 0.901 0.997 0.0366
rs28081 A 0.1510 1.006 0.943 1.073 0.8643
rs27037 A 0.2957 1.040 0.988 1.094 0.1314
rs27429 C 0.0598 0.943 0.855 1.041 0.2457
rs27524 A 0.3730 1.036 0.987 1.087 0.1497
rs25862 A 0.4488 0.996 0.951 1.044 0.8777
rs11135480 C 0.1321 1.032 0.964 1.105 0.3662
rs10515247 A 0.1323 1.033 0.964 1.106 0.3593
rs149078 A 0.2965 0.975 0.927 1.026 0.3280
rs27042 A 0.3655 0.959 0.914 1.007 0.0913
rs27044 G 0.2795 1.025 0.973 1.079 0.3557
rs17482078 A 0.2039 1.039 0.981 1.101 0.1883
rs42398 G 0.1470 1.009 0.945 1.077 0.7856
rs469783 G 0.4374 1.016 0.970 1.065 0.4956
rs10050860 A 0.2127 1.026 0.969 1.086 0.3862
rs13154629 A 0.2131 1.035 0.978 1.096 0.2276
rs30187 A 0.3478 1.019 0.971 1.070 0.4463
rs27434 A 0.2175 1.003 0.948 1.062 0.9069
rs26618 G 0.2370 0.975 0.923 1.030 0.3650
rs25866 A 0.2341 0.998 0.943 1.055 0.9369
rs26653 C 0.2835 0.984 0.934 1.036 0.5304
rs34753 G 0.2796 0.979 0.930 1.031 0.4259
rs28129 G 0.2804 0.979 0.930 1.031 0.4227
rs18036 G 0.2441 0.982 0.930 1.037 0.5188
rs152280 A 0.2085 0.991 0.936 1.049 0.7572
rs12520537 G 0.1537 0.987 0.926 1.053 0.6997
rs41135 G 0.4669 1.016 0.970 1.064 0.5092
rs34736 A 0.0648 0.929 0.845 1.021 0.1254
ERAP2
rs2911132 A 0.3726 1.014 0.967 1.064 0.5638
rs2042381 A 0.2733 1.022 0.970 1.077 0.4111
rs2927615 A 0.2404 1.027 0.973 1.084 0.3339
rs2927612 G 0.1168 0.993 0.924 1.067 0.8550
rs2549778 A 0.4292 1.005 0.959 1.053 0.8417
rs6861666 G 0.0781 1.014 0.930 1.106 0.7579
rs3733904 G 0.2117 0.965 0.911 1.022 0.2239
rs2549779 G 0.4880 0.983 0.939 1.030 0.4843
rs4869315 A 0.4241 0.969 0.924 1.015 0.1846
rs2549782 C 0.4093 1.047 0.999 1.097 0.0569
rs17408150 T 0.0560 1.050 0.948 1.162 0.3470
rs7714122 G 0.0648 0.999 0.908 1.098 0.9794
Adjusted for age, body mass index, history of diabetes, history of
hyperlipidemia, current smoking, exercise, alcohol use, education level,
current hormone use, and randomized treatment assignment. MA =minor;
MAF =minor allele frequency; OR = odds ratio; CI = conﬁdence interval.
Table 3: Cox regression analysis for all SNPs evaluated with
incident hypertension.
dbSNP MA MAF HR Lower95% CI
Upper
95% CI p-uncorrected
ERAP1
rs1559085 G 0.1413 0.997 0.957 1.037 0.8652
rs27851 G 0.0607 1.008 0.951 1.069 0.7869
rs3756623 C 0.0750 1.011 0.959 1.065 0.6970
rs754615 C 0.3907 0.996 0.968 1.025 0.7774
rs1862609 A 0.3129 0.990 0.961 1.021 0.5240
rs27772 G 0.3133 0.986 0.956 1.016 0.3421
rs28081 A 0.1510 1.011 0.973 1.051 0.5739
rs27037 A 0.2957 1.026 0.995 1.058 0.0967
rs27429 C 0.0598 1.008 0.95 1.070 0.7860
rs27524 A 0.3730 1.029 1.000 1.059 0.0537
rs25862 A 0.4488 0.992 0.965 1.021 0.5849
rs11135480 C 0.1321 1.021 0.980 1.064 0.3230
rs10515247 A 0.1323 1.021 0.980 1.064 0.3261
rs149078 A 0.2965 0.999 0.969 1.030 0.9572
rs27042 A 0.3655 0.996 0.968 1.026 0.8056
rs27044 G 0.2795 1.013 0.982 1.045 0.4108
rs17482078 A 0.2039 0.980 0.947 1.015 0.2539
rs42398 G 0.1470 1.009 0.970 1.050 0.6454
rs469783 G 0.4374 1.032 1.003 1.062 0.0291
rs10050860 A 0.2127 0.964 0.931 0.997 0.0351
rs13154629 A 0.2131 0.973 0.940 1.007 0.1182
rs30187 A 0.3478 1.026 0.996 1.056 0.0914
rs27434 A 0.2175 1.026 0.992 1.062 0.1403
rs26618 G 0.2370 0.987 0.955 1.020 0.4313
rs25866 A 0.2341 1.015 0.982 1.050 0.3732
rs26653 C 0.2835 1.019 0.988 1.051 0.2330
rs34753 G 0.2796 1.016 0.985 1.048 0.3224
rs28129 G 0.2804 1.016 0.985 1.048 0.3149
rs18036 G 0.2441 1.000 0.968 1.033 0.9944
rs152280 A 0.2085 1.013 0.978 1.048 0.4764
rs12520537 G 0.1537 1.028 0.989 1.068 0.1629
rs41135 G 0.4669 0.981 0.953 1.009 0.1740
rs34736 A 0.0648 1.001 0.945 1.060 0.9785
ERAP2
rs2911132 A 0.3726 0.986 0.958 1.015 0.3506
rs2042381 A 0.2733 1.010 0.979 1.042 0.5209
rs2927615 A 0.2404 0.958 0.927 0.990 0.0107
rs2927612 G 0.1168 0.991 0.949 1.036 0.6977
rs2549778 A 0.4292 0.998 0.970 1.026 0.8664
rs6861666 G 0.0781 1.028 0.976 1.082 0.2971
rs3733904 G 0.2117 0.991 0.957 1.026 0.6043
rs2549779 G 0.4880 0.994 0.966 1.022 0.6693
rs4869315 A 0.4241 0.987 0.960 1.016 0.3795
rs2549782 C 0.4093 1.019 0.991 1.048 0.1873
rs17408150 T 0.0560 1.046 0.985 1.111 0.1450
rs7714122 G 0.0648 1.030 0.974 1.090 0.2986
Adjusted for age, body mass index, history of diabetes, history of
hyperlipidemia, current smoking, exercise, alcohol use, education level,
current hormone use, and randomized treatment assignment. MA=minor;
MAF =minor allele frequency; HR = hazard ratio; CI = conﬁdence interval.
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p values <0.001. Results from the linear regression analyses
showed evidence for diﬀerential associations of four SNPs
(ERAP1: rs27524; ERAP2: rs3733904, rs4869315, and
rs2549782; all p-uncorrected <0.05) with baseline systolic
blood pressure levels (Online Supplementary Data Table 1)
and three SNPs (ERAP1: rs27851, rs27429, and rs34736, all
p-uncorrected <0.05) with baseline diastolic blood pressure
levels (Online Supplementary Data Table 2), respectively.
In the multivariable logistic regression analysis, ERAP1
rs27772 was shown to be associated with blood pressure
progression at 48 months (p-uncorrected= 0.0366; Table 2).
Results from the multivariable Cox regression analysis
showed evidence for an association of three SNPs
(ERAP1: rs469783 and rs10050860; ERAP2: rs2927615; all
p-uncorrected <0.05) with risk of incident hypertension
(Table 3). All SNPs evaluated were in agreement of
proportionality hazard assumption.
3.2. mRNA Expression Proﬁle in Cardiovascular Tissues by
ERAP Gene Variants. A total of 12 ERAP SNPs that showed
signiﬁcant eﬀects in the present study were evaluated (for
ERAP1: rs27524, rs27851, rs27429, rs30187, rs34736,
rs27772, rs469783, and rs10050860; for ERAP2: rs3733904,
rs4869315, rs2549782, and rs2927615) [31]. In the tibial
artery, all ERAP1 genetic variants were associated with signif-
icantly decreased ERAP1 mRNA expression (p < 0 0025)
except for rs27851 that showed an increase (Supplementary
Data Table 3). In all other tissues analyzed, at least four of
the SNPs were associated with decreased ERAP1 mRNA
levels. With regards to ERAP2, with the exception of
rs2927615, all other variants were signiﬁcantly associated
with reduced ERAP2 mRNA in the four tissue types tested.
Table 4 sequentially presents the association of the GTEx
SNP list with the phenotypic outcomes examined in the
present study. The overall ﬁndings suggest that genetic
variants of ERAP1 and ERAP2 that were associated with
blood pressure homeostasis may be predictive of lower
ERAP1 and ERAP2 expression levels.
We examined ERAP1 and ERAP2 gene expression levels
in the human endothelial cell line, EA.hy926, that were
stimulated with AngII. We observed that AngII incubation
signiﬁcantly increased ERAP1 but not ERAP2 mRNA levels
(Supplementary Data Figure 1). The AngII-stimulated
ERAP1 expression was blocked by preincubation with
losartan, an AngII type I receptor antagonist. Consequently,
our present results suggest that endothelial cell activation is
associated with the activation of the AngII type 1 receptor
and increased expression of ERAP1.
4. Discussion
Angiotensin II is one of the principal eﬀector molecules of
the renin-angiotensin-aldosterone system (RAAS). RAAS
plays a critical role in sodium, water homeostasis, and blood
pressure regulation. Indeed, disordered RAAS activation is
associated with endoplasmic reticulum stress, increased reac-
tive oxygen species, and inﬂammation, thus contributing to
the pathophysiology of stroke, hypertension, and heart fail-
ure [35–37]. Our results support the contention that ERAP
loci play a role in blood pressure homeostasis and the devel-
opment of hypertension. We provide evidence that the
genetic variation of ERAP was associated with baseline blood
pressure, blood pressure progression, and incident hyperten-
sion. In addition, ERAP1 SNPs were associated with altered
ERAP1 mRNA levels in vascular and adrenal tissues [31].
We thus posit that disordered ERAP1 levels may contrib-
ute to the pathophysiology of hypertension. Of impor-
tance, we report that in vitro activation of endothelial
cells by AngII leads to increases in ERAP1 mRNA via
activation of the AngII type 1 receptor in endothelial cells
(Supplementary Data Figure 1).
Diﬀerential associations of ERAP gene variants with
various outcomes have been reported (Table 5), providing
Table 4: Summary of association of the GTEx SNP list evaluated with the phenotypic outcomes examined in the present study.
ERAP1 Coronary∗ artery Tibial∗ artery Adrenal∗ gland Left∗ ventricle B-SBP∗∗ B-DBP∗∗ Prog∗∗ HTN∗∗
rs27524 0.0042 0.00087 <0.0001 <0.0001 0.0492 ns ns ns
rs27851 0.043 0.0023 0.13 0.66 ns 0.0083 ns ns
rs27429 0.08 0.0025 0.53 0.55 ns 0.0093 ns ns
rs30187 0.00022 <0.0001 <0.0001 <0.0001 ns ns ns ns
rs34736 0.10 0.00016 0.23 0.58 ns 0.0175 ns ns
rs27772 0.052 <0.0001 0.00028 0.18 ns ns 0.0366 ns
rs469783 0.0042 <0.0001 0.002 0.00075 ns ns ns 0.0291
rs10050860 0.88 <0.0001 0.18 0.023 ns ns ns 0.0351
ERAP2
rs3733904 <0.0001 <0.0001 0.0029 <0.0001 0.0090 ns ns ns
rs4869315 <0.0001 <0.0001 <0.0001 <0.0001 0.0108 ns ns ns
rs2549782 <0.0001 <0.0001 <0.0001 <0.0001 0.0320 ns ns ns
rs2927615 0.39 0.64 0.75 0.51 ns ns ns 0.0107
∗Values presented are p values for gene expression analysis from the GTEx Portal database (GTEx Analysis Release V6p). ∗∗Values presented are uncorrected
p values reported in the present investigation. B-SBP = baseline systolic blood pressure; B-DBP = baseline diastolic blood pressure; Prog = blood pressure
progression; HTN= incident hypertension; ns = p value >0.05.
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suggestive evidence for its involvement in blood pressure regu-
lation. Taken together with our data, genetic variants of ERAP,
in particular ERAP1, may modulate RAAS activity which in
turn may regulate ERAP1 levels through a potential negative
feedback mechanism. ERAP regulates bradykinin and AngII
levels. However, further studies are needed to characterize this
novel relationship between endoplasmic reticulum activation
and ERAP1 and RAAS activation for its potential therapeutic
applicability in blood pressure regulation.
As shown in Table 5, not all the published reports exam-
ined the same set of SNPs, nor did these studies comprehen-
sively and simultaneously examine the association of ERAP
gene loci with blood pressure progression, incident hyperten-
sion, and gene expression proﬁle. Furthermore, not all pub-
lished studies were conducted using comparable study
design(s) or in similar racial/ethnic sample population(s),
thus making a direct comparison and informative interpreta-
tion across studies diﬃcult. Given this situation, a possible
explanation for the apparent discrepancies is that the
observed allele frequencies for the SNPs examined may diﬀer
between various studies, which could be due to population/
ethnic diﬀerences/substructures.
Since several genome-wide association studies were
conducted to determine the genetic risk factors for blood
pressure [16–20], we further investigated the relationship
using thePhenotype–Genotype Integrator in theNCBIdbGaP
website [38–40]. Based on the dbGaP data repository, several
SNPs within the ERAP1 and ERAP2 gene loci were reported
to be associated with blood pressure (Supplementary Data
Table 4), further indicating the potential involvement of
ERAPs in blood pressure development.
The strengths of the present study are the overall sample
size, the biological relevance of the polymorphisms consid-
ered, the prospective design, and the complete long-term
follow-up among women. This is important as limited stud-
ies have addressed blood pressure outcomes in women exclu-
sively and growing evidence shows that women are at a
higher risk of developing hypertension-related cardiovascu-
lar diseases such as heart failure with preserved ejection frac-
tion than men are [41]. We also chose, on an a priori basis, to
present all our data simultaneously rather than focusing on
any one speciﬁc ﬁnding. Nonetheless, potential limitations
of our study require discussion. Limitations include general-
izability and potential bias. We examined only Caucasian
middle-aged and older women of distinct socioeconomic sta-
tus (health professionals), and our ﬁndings may not be gen-
eralizable to other populations with diverse ethnicity or
socioeconomic background. In our study, we had the ability
to detect, based on the present sample sizes, assuming 80%
power, at an alpha of 0.05, a hazards ratio of greater than
1.08 if the minor allele frequency is 0.50 and of greater than
1.09 if the minor allele frequency is 0.05 assuming a
univariable-additive model. Thus, we cannot rule out a low
risk associated with the SNPs tested. Finally, conﬁrmation
in other prospective studies is warranted. Nonetheless, our
present ﬁndings and the collective data reported in the
dbGaP consortium (Online Supplementary Data Table 4)
provide conﬁrmatory evidence for an association of ERAP1
and ERAP2 gene loci with blood pressure levels.
In conclusion, the present ﬁndings provide evidence for
the involvement of ERAP1 and ERAP2 gene loci in blood
pressure regulation and the pathogenesis of hypertension
with an added indication of ERAP1 gene locus as a potential
therapeutic target for blood pressure management.
Additional Points
Novelty and Signiﬁcance. What Is New? (i) Tagging single-
nucleotide polymorphisms (tSNPs) of the endoplasmic
reticulum aminopeptidase (ERAP) 1 and 2 is associated with
baseline systolic and diastolic blood pressure (BP). (ii) Three
ERAP1 and ERAP2 tSNPs are associated with risk of incident
hypertension. (iii) dbGaP analyses showed a genotype–phe-
notype association with ﬁve tSNPs and BP. (iv) Gene expres-
sion quantitative trait loci analyses revealed that these tSNPs
were associated with reduced ERAP1 and ERAP2 mRNA
expression levels in human cardiovascular tissue. What Is
Relevant? (i) ERAPs plays an important and well-described
role in immune function as they trim HLA-binding precur-
sors modulating their inclusion into MHC-I. (ii) ERAPs
metabolize a variety of cell surface receptors and peptides
including angiotensin-II. (iii) Small case–control studies pro-
vided evidence that polymorphic variants of ERAP1 and
ERAP2 are associated with preeclampsia and hypertension.
(iv) Recent data suggests that ERAP1 also is a mediator of
the hypotensive response to sepsis. Summary. This large,
prospective cohort study among initially healthy women
supports the contention that ERAP gene variation may be
useful for risk assessment of BP progression and the develop-
ment of hypertension.
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